Clear Search sequence regions


  • carfilzomib (13)
  • CD38 (1)
  • Dar3 (3)
  • daratumumab (3)
  • density- cell (1)
  • endocytosis (1)
  • LP 1 (2)
  • mice (2)
  • micelles (1)
  • multiple myeloma (13)
  • toxic effects (1)
  • Sizes of these terms reflect their relevance to your search.

    Multiple myeloma (MM) is the second most common hematological malignancy. For relapsed and refractory MM, a proteasome inhibitor, carfilzomib (CFZ), has become one of the few clinical options. CFZ suffers, nevertheless, metabolic instability and poor bioavailability and may induce severe cardiovascular and renal adverse events. Here, we report that daratumumab (Dar)-decorated polypeptide micelles (Dar-PMs) mediate the targeted delivery of CFZ to CD38-positive MM, effectively boosting its anti-MM efficacy. CFZ-loaded Dar-PMs (Dar-PMs-CFZ) exhibited an average diameter of ca. 80 nm and Dar density-dependent cell endocytosis and anti-MM activity, in which over 6-fold greater inhibitory effect to LP-1 and MM.1S MM cells than nontargeted PMs-CFZ control was achieved at a Dar density of 3.2 (Dar3.2-PMs-CFZ). Interestingly, Dar3.2-PMs-CFZ markedly enhanced the growth inhibition of orthotopic LP-1 MM in mice and significantly extended the median survival time compared with PMs-CFZ and free CFZ (95 days vs 60 and 54 days, respectively). In line with its high MM targetability and anti-MM efficacy, Dar3.2-PMs-CFZ revealed little toxic effects and effectively prevented osteolytic lesions. The antibody-targeted nanodelivery of a proteasome inhibitor appears to be an appealing strategy to treat multiple myeloma.

    Citation

    Ran Chen, Jiakun Yang, Yumin Mao, Xiaofei Zhao, Ru Cheng, Chao Deng, Zhiyuan Zhong. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma. Biomacromolecules. 2023 Nov 13;24(11):5371-5380

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37801632

    View Full Text